Pranlukast Antagonizes CD49f and Reduces Stemness in Triple-Negative Breast Cancer Cells

Inés Velázquez-Quesada,1,2 Angel J Ruiz-Moreno,1,3,4 Diana Casique-Aguirre,1 Charmina Aguirre-Alvarado,1 Fabiola Cortés-Mendoza,1,5 Marisol de la Fuente-Granada,6 Carlos García-Pérez,7 Sonia M Pérez-Tapia,2,8 Aliesha Gonzál...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Velázquez-Quesada I, Ruiz-Moreno AJ, Casique-Aguirre D, Aguirre-Alvarado C, Cortés-Mendoza F, de la Fuente-Granada M, García-Pérez C, Pérez-Tapia SM, González-Arenas A, Segura-Cabrera A, Velasco-Velázquez MA
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2020-05-01
Serija:Drug Design, Development and Therapy
Teme:
cd49f
alpha6 integrin
breast cancer stem cells
pranlukast
drug repositioning
triple-negative breast cancer cells.
Online pristup:https://www.dovepress.com/pranlukast-antagonizes-cd49f-and-reduces-stemness-in-triple-negative-b-peer-reviewed-article-DDDT
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items